Skip to main content
Explore URMC



Cameron Lab

Jian FuScott James Cameron, Ph.D, M.D.

Assistant Professor, Department of Medicine, Aab Cardiovascular Research Institute

2009 | M.D. | Medicine | SUNY Upstate Medical University

2003 | Ph.D. | Pharmacology | University of Rochester School of Medicine & Dentistry

Cameron profile

Research Overview

Our laboratory has funding from the National Institute of Heath to study signal transduction pathways in the cardiovascular system, and we apply this to the study of thrombotic disorders of the arterial and venous vasculature. Platelets are small anucleate blood particles which play an important role in thrombosis, hemostasis, and inflammation. Patients with ischemic and thrombotic disease of the coronary and peripheral vasculature are treated with anti-platelet drugs, yet some patients do not derive benefit from these drugs or they experience unexpected, off-target adverse events.

In addition, percutaneous removal of thrombotic burden from large arteries following heart attack occasionally fails to restore tissue perfusion (the no reflow phenomenon) and this is thought to involve microvascular occlusion by activated platelets. Patients with heart attack who do not require percutaneous intervention (coronary stenting), surprisingly, have a markedly greater long-term mortality compared to those patients who undergo percutaneous intervention. A possible explanation for these aberrant clinical events is that the platelet phenotype and platelet function in the inflammatory, ischemic environment may be different from platelets in normal healthy conditions or during acute disease. This may be a reason why current anti-platelet medications are not completely efficacious.

A major theme of our laboratory is personalized medicine where we aim to better define platelet function in disease states, paying particular attention to post-receptor signal transduction pathways. Active projects include understanding changes in platelet function in the post-myocardial infarct environment, in abdominal aortic aneurysm progression, in critical limb ischemia, and in hypoxic states. We employ contemporary cell biology, biochemistry, molecular biology, and animal models to address these questions. We work closely with our colleagues in clinical cardiology and vascular surgery. Our overall goal is to evaluate gaps in clinical care, then identify viable signaling pathways in human tissue for drug intervention, and finally to utilize animal models to test the hypothesis. We are a friendly, collaborative laboratory with a keen interest in the career development of all laboratory members.

Recent Publications

  1. Fernandez G. Cameron S., Nayda J., Cove C., Waits B. "Family Business of Aortopathies." Am J Med. 2015; 128(11): e13-5.
  2. Cameron SJ, Ture SK, Mickelsen D, Chakrabarti E, Modjeski KL, McNitt S, Seaberry M, Field DJ, Le NT, Abe JI, Morrell CN. "Platelet Extracellular Regulated Protein Kinase 5 Is a Redox Switch and Triggers Maladaptive Platelet Responses and Myocardial Infarct Expansion." Circulation. 2015 Jul 7; 132(1):47-58. Epub 2015 May 01.
  3. Cameron SJ, Laskurain E, Holcman K, Richeson JF, Mieszczanska H. "Treacherous Travelers: Emboli." The American journal of medicine. 2015 Jul; 128(7):695-8. Epub 2015 Mar 05.
  4. Cameron SJ. "Vascular Medicine: The Eye Cannot See What the Mind Does Not Know." Journal of the American College of Cardiology. 2015 Jun 30; 65(25):2760-3.
  5. Cameron SJ, Daimee U, Block RC. "A case of abdominal pain with dyslipidemia: difficulties diagnosing cholesterol ester storage disease." European review for medical and pharmacological sciences. 2015 19(14):2628-33